Abstract:Abstract Background Lung adenocarcinoma (LUAD) is one of the most common types in the world with a high mortality rate. Despite advances in treatment strategies, the overall survival (OS) remains short. Our study aims to establish a reliable prognostic signature closely related to the survival of LUAD patients that can better predict prognosis and possibly help with individual monitoring of LUAD patients. Methods Raw RNA-sequencing data were obtained from Fudan University and used as a training group. Differentially expressed genes (DEGs) for the training group were screened. The univariate, least absolute shrinkage and selection operator (LASSO), and multivariate cox regression analysis were conducted to identify the candidate prognostic genes and construct the risk score model. Kaplan–Meier analysis, time-dependent receiver operating characteristic (ROC) curve were used to evaluate the prognostic power and performance of the signature. Moreover, The Cancer Genome Atlas (TCGA-LUAD) dataset was further used to validate the predictive ability of prognostic signature. Results A prognostic signature consisting of seven prognostic-related genes was constructed using the training group. The 7-gene prognostic signature significantly grouped patients in high and low-risk groups in terms of overall survival in the training cohort [hazard ratio, HR = 8.94, 95% confidence interval (95% CI)] [2.041–39.2]; P = 0.0004), and in the validation cohort (HR = 2.41, 95% CI [1.779–3.276]; P < 0.0001). Cox regression analysis (univariate and multivariate) demonstrated that the seven-gene signature is an independent prognostic biomarker for predicting the survival of LUAD patients. ROC curves revealed that the 7-gene prognostic signature achieved a good performance in training and validation groups (AUC = 0.91, AUC = 0.7 respectively) in predicting OS for LUAD patients. Furthermore, the stratified analysis of the signature showed another classification to predict the prognosis. Conclusion Our study suggested a new and reliable prognostic signature that has a significant implication in predicting overall survival for LUAD patients and may help with early diagnosis and making effective clinical decisions regarding potential individual treatment.

A Seven Long-Noncoding RNA Signature Predicts Prognosis of Lung Squamous Cell Carcinoma.

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

A seven-long noncoding RNA signature predicts overall survival for patients with early stage non-small cell lung cancer.

A Novel Seven-Long Non-Coding RNA Signature Predicts Survival in Early Stage Lung Adenocarcinoma

The Prognostic Value of a Seven-Lncrna Signature in Patients with Esophageal Squamous Cell Carcinoma: a Lncrna Expression Analysis

Identification of a seven-lncRNAs panel that serves as a prognosis predictor and contributes to the malignant progression of laryngeal squamous cell carcinoma

A Seven-Lncrna Signature Predicts Overall Survival in Esophageal Squamous Cell Carcinoma

LncRNA Profile Study Reveals a Seven-Lncrna Signature Predicts the Prognosis of Patients with Colorectal Cancer

A 7-Lncrna Signature Associated with the Prognosis of Colon Adenocarcinoma

Identification of an Immune-related Seven-lncRNA Signature Predicting Prognosis and Tumor-infiltrating Immune Cells in Lung Adenocarcinoma

Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.

A seven-lncRNA signature for predicting Ewing’s sarcoma

Integrated Analysis of Competing Endogenous RNA Network Revealing Lncrnas As Potential Prognostic Biomarkers in Human Lung Squamous Cell Carcinoma

Six-long Non-coding RNA Signature to Predict the Prognosis of Lung Adenocarcinoma

A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.

Development of a Novel Prognostic Signature of Long Non-Coding RNAs in Lung Adenocarcinoma

Panel of Seven Long Noncoding RNA As a Candidate Prognostic Biomarker for Ovarian Cancer.

An Autophagy-Related Long Non-Coding RNA Prognostic Signature for Patients with Lung Squamous Carcinoma Based on Bioinformatics Analysis

A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)

Identification and Validation of a Novel Six-lncRNA-Based Prognostic Model for Lung Adenocarcinoma

A Five-Long Non-Coding RNA Signature with the Ability to Predict Overall Survival of Patients with Lung Adenocarcinoma.